Delving into the Latest Updates on Recombinant human anti-CTLA-4 monoclonal antibody(Beijing SL Pharmaceutical Co., Ltd.) with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms-

Target

CTLA4

Action

inhibitors

Mechanism

CTLA4 inhibitors(Cytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors)

Therapeutic Areas

Neoplasms

Active Indication

Advanced Malignant Solid Neoplasm

Inactive Indication-

Originator Organization

Beijing SL Pharmaceutical Co., Ltd.

Active Organization

Beijing SL Pharmaceutical Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的：评估MV049在晚期恶性实体瘤受试者中的安全性和耐受性；评估MV049在晚期恶性实体瘤受试者中的单次给药和多次给药药代动力学特征。次要目的：评估MV049在晚期恶性实体瘤受试者中的药效动力学特征、免疫原性及抗肿瘤活性。探索性目的：探索评估MV049对晚期恶性实体瘤的临床疗效。

[Translation]

Primary objective: To evaluate the safety and tolerability of MV049 in subjects with advanced malignant solid tumors; to evaluate the pharmacokinetic characteristics of MV049 after single and multiple administrations in subjects with advanced malignant solid tumors. Secondary objective: To evaluate the pharmacodynamic characteristics, immunogenicity and anti-tumor activity of MV049 in subjects with advanced malignant solid tumors. Exploratory objective: To explore and evaluate the clinical efficacy of MV049 in the treatment of advanced malignant solid tumors.

Start Date-

Sponsor / Collaborator

Mab-Venture Biopharm Co., Ltd.

[+1]

100 Clinical Results associated with Recombinant human anti-CTLA-4 monoclonal antibody(Beijing SL Pharmaceutical Co., Ltd.)

Login to view more data

100 Translational Medicine associated with Recombinant human anti-CTLA-4 monoclonal antibody(Beijing SL Pharmaceutical Co., Ltd.)

Login to view more data

100 Patents (Medical) associated with Recombinant human anti-CTLA-4 monoclonal antibody(Beijing SL Pharmaceutical Co., Ltd.)

Login to view more data

100 Deals associated with Recombinant human anti-CTLA-4 monoclonal antibody(Beijing SL Pharmaceutical Co., Ltd.)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Malignant Solid Neoplasm	Phase 1	China	Beijing SL Pharmaceutical Co., Ltd.	22 Jul 2019

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data